255 related articles for article (PubMed ID: 9219916)
1. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Levenson AS; Catherino WH; Jordan VC
J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):261-8. PubMed ID: 9219916
[TBL] [Abstract][Full Text] [Related]
2. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
Jiang SY; Parker CJ; Jordan VC
Breast Cancer Res Treat; 1993; 26(2):139-47. PubMed ID: 8219251
[TBL] [Abstract][Full Text] [Related]
3. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Levenson AS; Svoboda KM; Kwaan HC; Jordan VC
Cancer Lett; 1998 Mar; 125(1-2):215-20. PubMed ID: 9566718
[TBL] [Abstract][Full Text] [Related]
4. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
5. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
6. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Levenson AS; Jordan VC
Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
[TBL] [Abstract][Full Text] [Related]
7. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Catherino WH; Wolf DM; Jordan VC
Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
[TBL] [Abstract][Full Text] [Related]
8. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells.
Tonetti DA; Rubenstein R; DeLeon M; Zhao H; Pappas SG; Bentrem DJ; Chen B; Constantinou A; Craig Jordan V
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):47-55. PubMed ID: 14630090
[TBL] [Abstract][Full Text] [Related]
9. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.
Jiang SY; Jordan VC
J Natl Cancer Inst; 1992 Apr; 84(8):580-91. PubMed ID: 1556769
[TBL] [Abstract][Full Text] [Related]
10. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
Pearce ST; Liu H; Jordan VC
J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
12. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
13. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
[TBL] [Abstract][Full Text] [Related]
14. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.
Jiang SY; Wolf DM; Yingling JM; Chang C; Jordan VC
Mol Cell Endocrinol; 1992 Dec; 90(1):77-86. PubMed ID: 1301400
[TBL] [Abstract][Full Text] [Related]
15. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Tonetti DA; Jordan VC
Br J Cancer; 1998 Jun; 77(11):1812-9. PubMed ID: 9667651
[TBL] [Abstract][Full Text] [Related]
16. Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements.
Yoon K; Pallaroni L; Stoner M; Gaido K; Safe S
J Steroid Biochem Mol Biol; 2001 Jul; 78(1):25-32. PubMed ID: 11530281
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
18. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
19. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.
Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS
Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965
[TBL] [Abstract][Full Text] [Related]
20. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
